

VOLUME 36 NUMBER 5 SEPTEMBER 2009





Photos courtesy of the Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

7767 Published online by Cambridge University Press

PM 40007777

R 9824

u'ber-sharp

the power and precision of Leksell Gamma Knife® Perfexion™

Leksell Gamma Knife[®] Perfexion[™] and Elekta Axesse,[™] an image-guided radiosurgery treatment solution optimized for neurosurgery, are redefining stereotaxy in radiation medicine. Learn more about how Elekta's new line of stereotactic radiosurgery solutions are creating new possibilities for your most challenging cases by visiting www.elekta.com/proof



Redefining Stereotaxy in Radiation Medicine a case at a time

Neurological Sciences

Sciences Neurologiques

VOLUME 36 NUMBER 5 SEPTEMBER 2009

EDITORIALS

539 Progress and Gratitude

G. Bryan Young

540 Health-Related Quality of Life in MS: Issues and Interventions

Sharon Warren, Karen V.L. Turpin, Kenneth G. Warren

542 More than Meets the Eyes in Focal Epilepsy *Yves Robitaille*

REVIEW ARTICLE

543 Mitochondrial Ataxias

Josef Finsterer

ORIGINAL ARTICLES

554 Multiple Sclerosis: Change in Health-Related Quality of Life Over Two Years

Wilma M. Hopman, Helen Coo, Andrey Pavlov, Andrew Day, Catherine M. Edgar, Evelyn V. McBride, Donald G. Brunet

562 Gait Apraxia in Multiple Sclerosis

Nuhad E. Abou Zeid, Brian G. Weinshenker, B. Mark Keegan

566 α-B-Crystallin as a Tissue Marker of Epileptic Foci in Paediatric Resections

Harvey B. Sarnat, Laura Flores-Sarnat

575 Intra-Familial Incidence and Characteristics of Hot Water Epilepsy

Yuksel Kaplan, Semiha G. Kurt, Hatice Karaer, Basar Sarikaya, Nerses Bebek

582 Experiences from an International Tele-Epilepsy Collaboration

S. Nizam Ahmed, Carly Mann, Fowzia Siddiqui, Mughis Sheerani, Nadir Ali Syed, Thomas Snyder, S. Ather Enam, Warren Boling

587 Safety and Yield of Early Cessation of AEDs in Video-EEG Telemetry and Outcomes

Farzad Moien-Afshari, Robert Griebel, Venkat Sadanand, Mirna Vrbancic, Lizbeth Hernandez-Ronquillo, Noel Lowry, José F. Téllez Zenteno **593** Temporolimbic Activation by Intracranial Electrical Stimulation

Jorge A. Ure, André Olivier, Luis Felipe Quesney, Mauricio Bravo, Mónica Perassolo

599 Detection of Cognitive Impairment and Dementia Using the Animal Fluency Test: The DECIDE Study

Rolf Sebaldt, William Dalziel, Fadi Massoud, André Tanguay, Rick Ward, Lehana Thabane, Peter Melnyk, Pierre-Alexandre Landry, Benedicte Lescrauwaet

605 The Epidemiology of Hospitalized Head Injury in British Columbia, Canada

Leah A. Phillips, Don C. Voaklander, Colleen Drul, Karen D. Kelly

612 Can Admission S-100β Predict the Extent of Brain Damage in Head Trauma Patients?

E. Schültke, V. Sadanand, M.E. Kelly, R.W. Griebel, B.H.J. Juurlink

617 Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM

Gloria B. Roldán, James N. Scott, John B. McIntyre, Marisa Dharmawardene, Paula A. de Robles, Anthony M. Magliocco, Elizabeth S. Y. Yan, Ian F. Parney, Peter A. Forsyth, J. Gregory Cairncross, Mark G. Hamilton, Jacob C. Easaw

623 Pre-Operative Factors Affecting Resectability of Giant Intracranial Meningiomas

Alfredo Quiñones-Hinojosa, Tania Kaprealian, Kaisorn L. Chaichana, Nader Sanai, Andrew T. Parsa, Mitchel S. Berger, Michael W. McDermott

631 Effects of Surgical Excision and Radiation of Medulloblastoma Cell Invasiveness

> Adrianna Ranger, Warren McDonald, Glenn S. Bauman, Rolando Del Maestro

638 Underlying Venous Pathology Causing Perimesencephalic Subarachnoid Hemorrhage

Jaejoon Lee, Eun-Mi Koh, Chin-Sang Chung, Seung-Chul Hong, Yong-Bum Kim, Pil-Wook Chung, Bum-Chun Suh, Heui-Soo Moon

643 Cine Phase-Contrast MR Images Failed to Predict Clinical Outcome Following ETV

Xiao Di, M. Ragab, Mark G. Luciano

Neurological Sciences

Sciences Neurologiques

VOLUME 36 NUMBER 5 SEPTEMBER 2009

NEUROIMAGING HIGHLIGHT

648 Submitted by: Andrew Leung, Christen Shoesmith, Miguel Bussière

BRIEF COMMUNICATIONS (formerly Case Reports)

651 A Case of Diabetic Muscle Infarction

Abdulaziz Qasem, Farzad Tanha, Hannah Briemberg

654 Recurrent PNET with MGMT Methylation Responds to Temozolomide

Jiwon Oh, Juan M. Bilbao, May N. Tsao, Mahmood Fazl, Marie-Christine Guiot, Rolando F. Del Maestro, James R. Perry

658 Cerebellar Liponeurocytoma with High Proliferation Index: Treatment Options

C.E. Châtillon, M.C. Guiot, D. Roberge, R. Leblanc

662 Recurrent Cerebellar Liponeurocytoma with Supratentorial Extension

Faten Limaiem, Selma Bellil, Inès Chelly, Khadija Bellil, Amina Mekni, Hafedh Jemel, Slim Haouet, Moncef Zitouna, Nidhameddine Kchir

REFLECTIONS

666 Passage of Time - A Poem Donald F. Weaver

667	Books Received / Books Reviewed
670	Congress Thank You
A-11	Advertisers Index
A-8	Board of Directors/Committee Chairs
A-12	Calendar of Events
A-11	Classified Ads
A-9, A-10	Information for Authors
IBC	CNSF Sponsors

JOURNAL COVER

We are investigating different options for the cover of the Journal and thought it might be appropriate to include pictures of major Canadian Cities and/or Universities as taken by our readers.

If you are interested in submitting pictures, please send them to maggie-mccallion@cnsfederation.org in high resolution format, (i.e. tif or jpeg). Please also indicate your willingness to provide these pictures free of charge. Picture 'acknowledgement' will be provided. The only once-daily treatment for PARKINSON'S DISEASE

AZILECT[®]: Efficacy and convenient once-daily dosing

AZILECT® (rasagiline mesylate) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.

AZILECT® is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, cyclobenzaprine, sympathomimetic amines, antidepressants and other MAO inhibitors. Patients taking AZILECT® should not undergo elective surgery requiring general anesthesia. AZILECT® is contraindicated in patients with pheochromocytoma.' AZILECT® may cause hallucinations and as adjunct to levodopa there is the possibility of increased dyskinesia and postural hypotension. AZILECT® should not be used at daily doses exceeding the maximum recommended (1 mg/day) because of the risks associated with nonselective inhibition of MAO. Patients taking ciprofloxacin and other CYP1A2 inhibitors should use 0.5 mg daily of AZILECT®.

No significant differences in safety profile were observed based on age or gender. Overall, in phase IVIII clinical triats, the long-term safety profile was similar to that observed with shorter duration exposure.

The most commonly observed adverse events that occurred in $\geq 5\%$ of patients and were at least 1.5 times the incidence in the placebo group were flu syndrome

(5%, 1%), arthralgia (7%, 4%), depression (5%, 2%), dyspepsia (7%, 4%) and falls (5%, 3%) in patients receiving AZILECT* 1 mg as monotherapy; and dyskinesia (18%, 10%), accidental injury (12%, 5%), weight loss (9%, 3%), postural hypotension (9%, 3%), vomiting (7%, 1%), anorexia (5%, 1%), arthralgia (8%, 4%), addominal pain (5%, 1%), nausea (12%, 8%), constipation (9%, 5%), dry mouth (6%, 3%), rash (6%, 3%) ecchymosis (5%, 3%), somnolence (6%, 4%) and paresthesia (5%, 3%) for AZILECT* 1 mg as adjunct therapy.

† Comparative clinical significance unknown.



AZILECT* is a registered trademark of Teva Pharmaceutical Industries Ltd. and is used under licence. TEVA and the design version thereof are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under licence. @2009 Teva Neuroscience G.P. – S.E.N.C. Montreal, Ouebec. H2A 3L4

(6%, 4%) and AZILECT (rasagiline tablets)

LI IIIII

Neurological Sciences

Sciences Neurologiques

VOLUME 36 NUMBER 5 SEPTEMBER 2009

Editor-in-Chief/Rédacteur en chef G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB Michael Shevell MONTREAL, QC Timothy J. Benstead HALIFAX, NS Mike Poulter LONDON, ON Serge Gauthier VERDUN, QC Mandar Jog LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB James A. Sharpe TORONTO, ON Robert G. Lee CALGARY, AB Robert T. Ross WINNIPEG, MB (Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'éditorial

Jorge Burneo LONDON, ON Richard Desbiens QUEBEC CITY, QC David Fortin SHERBROOKE, QC Mark Hamilton CALGARY, AB Robert Hammond LONDON, ON Hans-Peter Hartung DUSSELDORF, GERMANY Michael Hill CALGARY, AB Alan C. Jackson WINNIPEG, MB Daniel Keene OTTAWA, ON Terence Myles CALGARY, AB James Perry TORONTO, ON Oksana Suchowersky CALGARY, AB Brian Toyota VANCOUVER, BC Brian Weinshenker ROCHESTER, MN, USA Samuel Wiebe CALGARY, AB Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie Richard Farb TORONTO, ON David Pelz LONDON, ON

Neuropathological Conference/Conférence sur la neuropathologie Robert Hammond LONDON, ON

Book Review/Critiques de livres Andrew Kirk SASKATOON, SK

Critically Appraised Topic Summaries (CATS)

Jorge Burneo LONDON, ON Mary Jenkins LONDON, ON

We acknowledge the assistance of the Government of Canada through the Publications Assistance Program towards our mailing costs. Canada

Editorial Review Board/Conseil de Revue d'éditorial

Donald Brunet KINGSTON, ON Lionel Carmant MONTREAL, QC Colin Chalk MONTREAL, QC K. Ming Chan EDMONTON, AB Robert Chen TORONTO, ON Mary Connolly VANCOUVER, BC Joseph Dooley HALIFAX, NS Daryl Fourney SASKATOON, SK Hannah Glass SAN FRANCISCO, CA, USA Alan Goodridge ST. JOHN'S, NL Ian Grant HALIFAX, NS Alan Guberman OTTAWA, ON John Hurlbert CALGARY, AB Manouchehr Javidan VANCOUVER, BC Patrick McDonald WINNIPEG, MB Martin McKeown VANCOUVER, BC Joseph Megyesi LONDON, ON Vivek Mehta EDMONTON, AB Steven Miller VANCOUVER, BC Neelan Pillay CALGARY, AB Christopher Power EDMONTON, AB Alex Raiput SASKATOON, SK Jean Raymond MONTREAL, OC Gary Redekop VANCOUVER, BC Mark Sadler HALIFAX, NS Harvey Sarnat CALGARY, AB John Stewart VANCOUVER, BC Jeanne Teitelbaum MONTREAL, QC Eve Tsai OTTAWA, ON Shannon Venance LONDON, ON Matt Wheatley EDMONTON, AB Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, Chief Executive Officer Maggie McCallion, Designer/ Production Coordinator Cindy Leschyshyn, Editorial Coordinator

Advertising representative/Représentant de publicité: Brett Windle

Corporate Development Coordinator Tel (403) 229-9575 Fax (403) 229-1661 E-mail: brett-windle@cnsfederation.org The official journal of: / La Revue officielle de: The Canadian Neurological Society La Société Canadienne de Neurologie The Canadian Neurosurgical Society La Société Canadienne de Neurochirurgie The Canadian Society of Clinical Neurophysiologists La Société Canadienne de Neurophysiologie Clinique The Canadian Association of Child Neurology L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at: Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situe en permanence à: 7015 Macleod Trail SW, Suite 709, Calgary AB, Canada T2H 2K6.

The Canadian Journal of Neurological Sciences is published bimonthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See www.cjns.org for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org COPYRIGHT© 2009 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail Agreement no: 40007777; PAP Registration no: 09824. Postage paid at Calgary, Alberta. This journal is indexed by AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerpMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsycInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel forpour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web:www.cjns.org. DROITS D'AUTEUR© 2009: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'authorisation du Journal Canadien des Sciences Neurologiques. Posté sous poste-publications: numéro de convention: 40007777; numéro d'enregistrement PAP 09824. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerpMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN NSCI, PE&ON, PN&I, ProtozoAb, PsycInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem.

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE Calgary, Alberta T2G 4B9

Pr**MAXALT RPD**® (rizatriptan benzoate): **The Most Dispensed Non-tablet Migraine** Formulation in Canada¹

MAXALT[®] 10 mg and

MAXALT RPD® 10 mg ALSO AVAILABLE IN

Fast dissolving RPD wafer can be taken anytime, anywhere^{2,*}

ALSO AVAILABLE IN TABLET FORMULATION.

MAXALT® (rizatriptan benzoate) is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT[®] is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of MAXALT® have not been established for cluster headache, which is present in an older, predominantly male population.

MAXALT[®] is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases should not receive MAXALT®.

MAXALT® is also contraindicated in patients with uncontrolled or severe hypertension.

MAXALT® is contraindicated in co-administration with monoamine oxidase (MAO) inhibitors within 2 weeks after discontinuation of treatment, and within 24 hours of administration of 5-HT1 agonists or ergot-type medications. For a complete list of contraindications, please consult the Product Monograph.


The recommended single adult dose is 5 mg. The maximum recommended single dose is 10 mg.

Please visit our website at: www.merckfrosst.com









The most common adverse events during treatment with MAXALT® (rizatriptan benzoate) tablets 10 mg were dizziness (8.9%), somnolence (8.4%), asthenia/fatigue (6.9%), nausea (5.7%) and pain/pressure sensation (chest, 3.1%; neck/throat/jaw, 2.5%; upper limb, 1.8%).

The most common adverse events during treatment with ^{Pr}MAXALT RPD® (rizatriptan benzoate) wafers 10 mg were dizziness (8.6%), nausea (7.0%), dry mouth (6.0%), somnolence (5.3%), asthenia/fatigue (3.6%), and pain/ pressure sensation (chest, 1.7%; neck/throat/jaw, 2.0%; upper limb, 2.0%).

MAXALT RPD® wafers contain phenylalanine (a component of aspartame).

*The wafer will dissolve rapidly and be swallowed with saliva. No liquid is needed to take the wafer.² RPD = Rapidly dissolving

References: 1. Brogan Inc. Geographic Prescription Monitor (GPM®) October 2007 to September 2008. 2. Data on file, Merck Frosst Canada Ltd.: Product Monograph, MAXALT®, 2008.

BEFORE PRESCRIBING MAXALT®, PLEASE CONSULT THE ENCLOSED PRESCRIBING INFORMATION

PRODUCT MONOGRAPH AVAILABLE FOR DOWNLOAD AT www.merckfrosst.com ®Registered Trademarks of Merck & Co., Inc. Used under license.

MXT-08-CDN-34381016-JA

https://doi.org/10.1017/S0317167100117767 Published online by Cambridge University Press A-5

Choose ME migraine therapy that has demonstrated rapid, reliable relief."

- Demonstrated headache response as quickly as 30 minutes postdose vs. placebo (RELPAX 40 mg: 9%; placebo: 4%, p<0.05)^{1.2†}
- Provided greater relief of associated symptoms vs. sumatriptan 100 mg at 2 hours (absence of nausea: 74% vs. 67%, p<0.01; absence of photophobia: 71% vs. 63%, p<0.01; absence of phonophobia: 74% vs. 67%, p<0.01)^{3‡}
- Demonstrated superior functional response at 2 hours vs. sumatriptan 100 mg (68% vs. 61%, p<0.01; 63% vs. 46%, p<0.005)^{3,41§}

RELPAX tablets are indicated for the acute treatment of migraine with or without aura in adults. RELPAX tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of RELPAX tablets have not been established for cluster headache, which is present in an older, predominantly male population. Among 5984 patients who treated a single migraine headache with RELPAX 20 mg, 40 mg or 80 mg tablets in short-term, placebo-controlled trials, the most common and dose-related adverse events reported with treatment with RELPAX were asthenia (7.2%), nausea (7.8%), dizziness (5.7%) and somnolence (5.2%). RELPAX 80 mg is not an available dose. The maximum daily dose is 40 mg.

RELPAX is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) or uncontrolled or severe hypertension should not receive RELPAX. Serious cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm and death, have occurred within a few hours following the use of other 5-HT₁ agonists. These events are extremely rare and have been commonly reported in patients with CAD risk factors or a family history of CAD. RELPAX is contraindicated within 72 hours of treatment with potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). RELPAX is contraindicated within 72 hours with drugs that have demonstrated potent CYP3A4 inhibition and have this potent effect described in the CONTRAINDICATIONS, or WARNINGS AND PRECAUTIONS sections of their labeling. RELPAX is contraindicated within 24 hours of treatment with another 5-HT₁ agonist, an ergotamine-containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide. RELPAX is contraindicated in patients with hemiplegic, ophthalmoplegic or basilar migraine, patients with severe hepatic impairment, and those with known hypersensitivity to eletriptan or any of its inactive ingredients.

+ In a multicentre, double-blind, placebo-controlled, parallel-group clinical trial, 1334 outpatients with a diagnosis of migraine were randomized to receive RELPAX 20 mg, 40 mg, or 80 mg, or placebo for the treatment of up to 3 migraine attacks. The efficacy, consistency, tolerability and safety of RELPAX were evaluated.

‡ In a randomized, double-blind, double-dummy, parallel-group study conducted in 2113 patients with a diagnosis of migraine. Subjects were randomized to receive RELPAX 40 mg, sumatriptan 100 mg or placebo for the treatment of a single migraine attack.

§ In a randomized, double-blind, double-dummy, placebo-controlled study conducted in 1008 patients with a history of migraine. Subjects were randomized to receive RELPAX 40 mg or 80 mg, sumatriptan 50 mg or 100 mg, or placebo to treat up to 3 migraine attacks.

For complete prescribing information, please refer to the Product Monograph. The Product Monograph is available upon request.



Pfize

[™] Pfizer Inc, used under license RELPAX® Pfizer Products Inc., owner/Pfizer Canada Inc., licensee © 2009 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5

Working together for a healthier world™

See prescribing summary on page A-27-30

Thank you for joining us at this years Congress and we look forward to seeing you at our next Congress in Quebec City!

SPECTACULAR QUEBEC CITY A WHOLE NEW EXPERIENCE

Some travel destinations just seize the imagination. Their beauty is breathtaking. They evoke wonder and excitement. They are vibrant and alive. They are warm and welcoming. But few do it all as effortlessly as naturally as Quebec, the unique walled city on the St. Lawrence River. No other destination in the world offers Quebec's compelling mix of features and attractions.

Canadian Neurological Sciences Federation



IL MILL

CANADIAN NEUROLOGICAL SCIENCES FEDERATION FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA 45th Annual Congress

Quebec City, Quebec June 8-11, 2010


GOURMET QUEBEC CITY

Quebecers love fine food - and it shows. Every meal in Quebec City is truly a taste sensation. Although Quebec City and its surrounding region are often referred to as North America's fine dining capital, they would also be called its casual dining capital, its sidewalk cafe capital, its bistro capital, its wine and cheese capital...In fact, food in Quebec City is one of the great pleasures of life - and one of the best reasons for travelling to the city and area time and again!



The Canadian Neurological Sciences Federation (CNSF) and Neurological Sciences Foundation of Canada (NSFC)

2009 - 2010 Board of Directors and Committee Chairs



George Elleker • CNSF President

- NSFC President
- CSCN Past President



Garth Bray • CNSF Vice-President

- NSFC Vice-President
- CNS Member



- CNSF Vice-President
 NSFC Vice-President
- CNSS Past President
 - CNSS Past Presiden



Mary Connolly • CNSF Board Member • NSFC Board Member • CACN President



Sharon Whiting • CNSF Board Member

- NSFC Board Member
- CACN Vice-President



J. Max Findlay • CNSF Board Member • NSFC Board Member • CNSS President



Seyed Mirsattari • CNSF Board Member • NSFC Board Member • CSCN Vice-President



Dan Morin • CEO Non-voting



CNSF Board Member
 NSFC Board Member
 CNSS Vice-President



Trevor Steve

- CNSF Board Member
 NSFC Board Member
- Residente' Bon CNS
- Residents' Rep. CNS



G. Bryan Young • Journal Editor-in-Chief • CNS & CSCN Member



Lyle Weston • CNSF Board Member • NSFC Board Member • CNS President



Shobhan Vachhrajani • Residents' Rep. CNSS



Sarah Kirby • CNSF Board Member • NSFC Board Member • CNS Vice- President



Vijay Ramaswamy • Residents' Rep. CACN

Colin Chalk

CNS Member

CNSE Professional

Development Committee Chair





Andrew Kirk • CNSF/NSFC Past President - Non-voting



Richard Riopelle • CBANHC Chair

Legend:

CNSF - Canadian Neurological Sciences Federation; NSFC - Neurological Sciences Foundation of Canada; CNS - Canadian Neurological Society; CNSS - Canadian Neurosurgical Society; CSCN - Canadian Society of Clinical Neurophysiologists; CACN - Canadian Association of Child Neurology; CBANHC - Canadian Brain and Nerve Health Coalition

CNSF Scientific Program

Michael Hill

Committee Chair

CNS Member